IN2014DN06942A - - Google Patents
Info
- Publication number
- IN2014DN06942A IN2014DN06942A IN6942DEN2014A IN2014DN06942A IN 2014DN06942 A IN2014DN06942 A IN 2014DN06942A IN 6942DEN2014 A IN6942DEN2014 A IN 6942DEN2014A IN 2014DN06942 A IN2014DN06942 A IN 2014DN06942A
- Authority
- IN
- India
- Prior art keywords
- crystal form
- methyltetrahydrofolate
- salt
- angles
- ray diffraction
- Prior art date
Links
- 239000013078 crystal Substances 0.000 abstract 5
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical class C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 abstract 2
- 238000002441 X-ray diffraction Methods 0.000 abstract 2
- JMNIIIQOMSQWJN-ZEXVLMPOSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Ca+2].C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1.C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 JMNIIIQOMSQWJN-ZEXVLMPOSA-L 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- KJUCVIHHEMCARO-ZEXVLMPOSA-L strontium (4S)-4-[[4-[[(6S)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Sr+2].CN1C=2C(NC(=NC2NC[C@@H]1CNC1=CC=C(C(N[C@@H](CCC(=O)[O-])C(=O)O)=O)C=C1)N)=O.CN1C=2C(NC(=NC2NC[C@@H]1CNC1=CC=C(C(N[C@@H](CCC(=O)[O-])C(=O)O)=O)C=C1)N)=O KJUCVIHHEMCARO-ZEXVLMPOSA-L 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B30/00—Production of single crystals or homogeneous polycrystalline material with defined structure characterised by the action of electric or magnetic fields, wave energy or other specific physical conditions
- C30B30/06—Production of single crystals or homogeneous polycrystalline material with defined structure characterised by the action of electric or magnetic fields, wave energy or other specific physical conditions using mechanical vibrations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/14—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Metallurgy (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Mechanical Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210019038.4A CN102584826B (zh) | 2012-01-20 | 2012-01-20 | (6s)-5-甲基四氢叶酸盐晶型及其制备方法 |
| CN201210018941.9A CN102775407B (zh) | 2012-01-20 | 2012-01-20 | 稳定的无定型5-甲基四氢叶酸盐及其制备方法 |
| CN201210125133.2A CN102702200B (zh) | 2012-04-25 | 2012-04-25 | (6rs)-5-甲基四氢叶酸钙盐晶型及其制备方法 |
| PCT/CN2012/086794 WO2013107236A1 (zh) | 2012-01-20 | 2012-12-17 | （6s）-5-甲基四氢叶酸盐晶型及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN06942A true IN2014DN06942A (enExample) | 2015-04-10 |
Family
ID=48798580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN6942DEN2014 IN2014DN06942A (enExample) | 2012-01-20 | 2012-12-17 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9150982B2 (enExample) |
| EP (1) | EP2805952B1 (enExample) |
| JP (1) | JP6166736B2 (enExample) |
| KR (1) | KR101694710B1 (enExample) |
| BR (1) | BR112014017939A2 (enExample) |
| CA (1) | CA2861891C (enExample) |
| ES (1) | ES2715599T3 (enExample) |
| HR (1) | HRP20190317T1 (enExample) |
| IN (1) | IN2014DN06942A (enExample) |
| PL (1) | PL2805952T3 (enExample) |
| WO (1) | WO2013107236A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015193778A1 (en) | 2014-06-16 | 2015-12-23 | Mylan Laboratories Ltd. | Crystalline form of levomefolate calcium |
| JP6960853B2 (ja) * | 2014-09-04 | 2021-11-05 | ▲連雲▼港金康和信▲薬業▼有限公司Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. | （６ｓ）−５−メチルテトラヒドロ葉酸又はその塩の組成物及びその調製と応用 |
| DK3609894T3 (da) * | 2017-03-31 | 2024-09-09 | Merck Patent Gmbh | Krystallinsk natriumsalt af 5-methyl-(6s)-tetrahydrofolsyre |
| US11377448B2 (en) | 2017-03-31 | 2022-07-05 | Merck Patent Gmbh | Crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid |
| PT3817814T (pt) * | 2018-07-06 | 2023-12-28 | Merck Patent Gmbh | Sais cristalinos de acido 5-metil- (6s) -tetra-hidrofólico e de éster etílico de l-valina |
| CN112007163B (zh) * | 2019-08-06 | 2023-07-28 | 连云港金康和信药业有限公司 | 用于治疗非洲猪瘟的药物组合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223500A (en) | 1977-02-22 | 1993-06-29 | Bioresearch S.P.A. | Stable pharmaceutical composition of alkaline or alkaline earth 5-methyl tetrahydrofolate |
| US5471001A (en) * | 1994-12-15 | 1995-11-28 | E. I. Du Pont De Nemours And Company | Crystallization of adipic acid |
| CH693905A5 (de) * | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
| DE10137017A1 (de) * | 2001-07-30 | 2003-02-20 | Basf Ag | Kristallisationsverfahren zur Einstellung kleiner Partikel |
| WO2006120520A1 (en) * | 2005-05-06 | 2006-11-16 | Glenmark Pharmaceuticals Limited | Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same |
| CN100336814C (zh) | 2005-11-23 | 2007-09-12 | 天津大学 | 溶剂超声协同作用制备球状结晶核黄素方法 |
| KR100878140B1 (ko) * | 2007-01-29 | 2009-01-12 | 한미약품 주식회사 | 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 |
| CH698729B1 (de) | 2007-05-30 | 2009-10-15 | Cerbios Pharma Sa | Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure. |
| CN102584826B (zh) | 2012-01-20 | 2015-04-29 | 连云港金康医药科技有限公司 | (6s)-5-甲基四氢叶酸盐晶型及其制备方法 |
| CN102702200B (zh) | 2012-04-25 | 2014-11-12 | 连云港金康和信药业有限公司 | (6rs)-5-甲基四氢叶酸钙盐晶型及其制备方法 |
| CN102775407B (zh) | 2012-01-20 | 2015-08-05 | 连云港金康医药科技有限公司 | 稳定的无定型5-甲基四氢叶酸盐及其制备方法 |
-
2012
- 2012-12-17 PL PL12865798T patent/PL2805952T3/pl unknown
- 2012-12-17 HR HRP20190317TT patent/HRP20190317T1/hr unknown
- 2012-12-17 IN IN6942DEN2014 patent/IN2014DN06942A/en unknown
- 2012-12-17 US US14/373,262 patent/US9150982B2/en active Active
- 2012-12-17 WO PCT/CN2012/086794 patent/WO2013107236A1/zh not_active Ceased
- 2012-12-17 KR KR1020147023261A patent/KR101694710B1/ko active Active
- 2012-12-17 BR BR112014017939-5A patent/BR112014017939A2/pt not_active Application Discontinuation
- 2012-12-17 EP EP12865798.8A patent/EP2805952B1/en active Active
- 2012-12-17 CA CA2861891A patent/CA2861891C/en active Active
- 2012-12-17 ES ES12865798T patent/ES2715599T3/es active Active
- 2012-12-17 JP JP2014552484A patent/JP6166736B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2805952A4 (en) | 2015-07-01 |
| KR101694710B1 (ko) | 2017-01-10 |
| BR112014017939A8 (pt) | 2017-07-11 |
| US20150018357A1 (en) | 2015-01-15 |
| EP2805952A1 (en) | 2014-11-26 |
| JP6166736B2 (ja) | 2017-07-19 |
| US9150982B2 (en) | 2015-10-06 |
| CA2861891A1 (en) | 2013-07-25 |
| WO2013107236A1 (zh) | 2013-07-25 |
| HRP20190317T1 (hr) | 2019-05-03 |
| KR20140113740A (ko) | 2014-09-24 |
| BR112014017939A2 (pt) | 2021-05-25 |
| JP2015506941A (ja) | 2015-03-05 |
| CA2861891C (en) | 2018-06-19 |
| ES2715599T3 (es) | 2019-06-05 |
| EP2805952B1 (en) | 2019-02-06 |
| PL2805952T3 (pl) | 2019-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN06942A (enExample) | ||
| PH12019500681A1 (en) | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof | |
| WO2011107186A3 (de) | Verbindungen für elektronische vorrichtungen | |
| MY180083A (en) | Tetrahydropyrrolothiazine compounds | |
| NZ743374A (en) | Crystalline forms of diazabicyclooctane derivative and production process thereof | |
| PH12019502093A1 (en) | Novel ester compounds, method for the production thereof and use thereof | |
| TN2013000400A1 (en) | Imidazopyridazines as akt kinase inhibitors | |
| PH12015500363A1 (en) | Prodrugs of amino quinazoline kinase inhibitor | |
| AU2014224456A8 (en) | Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same | |
| MX2014011921A (es) | Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos. | |
| TN2012000435A1 (en) | Agomelatine hydrochloride hydrate and preparation thereof | |
| IL290973A (en) | An industrial process for the preparation of estradiol with a high degree of purity | |
| MX359069B (es) | Sal y formas cristalinas de inhibidor de quinasa tipo polo-4. | |
| MX2016002718A (es) | Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc). | |
| MX378363B (es) | Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo. | |
| AU2014371081A1 (en) | Polyoxalates and a Process for the Production Thereof | |
| AU2018374682A1 (en) | Salts of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno(3,2-d)pyrimidine-7-carboxamide, and crystalline forms thereof | |
| UA113988C2 (xx) | Спосіб стабілізації бета-напівгідрату штукатурного гіпсу | |
| NZ720340A (en) | Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crystalline forms thereof | |
| IN2015DN00950A (enExample) | ||
| HK1207079A1 (en) | An improved process for the preparation of carbapenem antibiotic | |
| WO2015150907A3 (en) | High purity synthetic fluorite and process for preparing the same | |
| EP4282973A3 (en) | Processes for the preparation of pyrimidinylcyclopentane compounds | |
| MX349752B (es) | Proceso para la preparacion de 3-metilsulfonilpropionitrilo. | |
| WO2017093866A3 (en) | An improved process for the preparation of indigo carmine |